Bile News and Research

RSS

Advancements in liquid biopsy for detecting pancreatic incidentalomas

In recent research published in eGastroenterology, Dr. J-Matthias Löhr and colleagues provide an in-depth review of diagnostic methods for pancreatic incidentaloma-;incidental findings often detected during imaging scans intended for other conditions.

8 Nov 2024

Review: The multifaceted roles of bilirubin in liver health and disease

Bilirubin, the byproduct of hemoprotein breakdown, particularly hemoglobin, is a critical marker in diagnosing, prognosing, and managing liver diseases.

6 Nov 2024

New stent sensor developed to detect blockages early

Stents to treat various blockages in the human body can themselves become blocked, but a new sensor developed at the University of Michigan for stents that are used in the bile duct may one day help doctors detect and treat stent blockages early, helping keep patients healthier.

1 Nov 2024

3D tumor mapping reveals new insights into cancer biology and treatment

A new analysis led by researchers at Washington University School of Medicine in St. Louis has revealed detailed 3D maps of the internal structures of multiple tumor types. These cancer atlases reveal how different tumor cells -; and the cells of a tumor's surrounding environment -; are organized, in 3D, and how that organization changes when a tumor spreads to other organs.

1 Nov 2024

Ipsen's elafibranor recommended for use in patients with rare liver disease

Ipsen announced today that the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. This makes elafibranor the first medicine for PBC approved for use on the NHS in nearly a decade.

26 Oct 2024

HER2-postive breast cancer drugs show promise for bile duct cancer treatment

Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

23 Oct 2024

Gut microbiota composition linked to PCOS subtypes: regional and testosterone-based variations found

This analysis uncovers gut microbiota variations in PCOS, emphasizing the role of testosterone and regional factors in understanding the disorder's complexity.

22 Oct 2024

Liver function discovery could revolutionize treatments for cardiovascular disease

A new discovery about how the liver flushes cholesterol from the body could lead to more effective treatments for cardiovascular disease – the leading cause of death worldwide.

18 Oct 2024

New grant aims to transform treatment for liver cancer

Currently, there are a few available treatment options for liver cancer, including a combination of immunotherapies and a class of drugs known as tyrosine kinase inhibitors (TKIs), but their long-term effects are limited.

17 Oct 2024

Chronic stress disrupts gut microbiota, promoting colorectal cancer growth

Cutting-edge research has uncovered how chronic stress disrupts the balance of gut microbiota to speed up the progression of colorectal cancer (CRC), opening new avenues for CRC prevention and treatment.

13 Oct 2024

How gut microbiome and fiber diversity shape chronic disease outcomes

Review explores how different types of dietary fibers interact with the gut microbiome, influencing chronic disease risks like obesity, cancer, and cardiometabolic conditions, while emphasizing the need for personalized dietary interventions.

13 Oct 2024

Researchers uncover key bacteria driving success of fecal microbiota transplants

Fecal microbiota transplants, or FMTs, are a magic bullet for patients with recurring infections from Clostridioides difficile (C. diff), but researchers are only beginning to understand why.

9 Oct 2024

New pipeline of drug candidates offers hope for effective MASLD treatments

Non-alcoholic fatty liver disease (NAFLD), recently reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD), has become the most prevalent chronic liver disease globally.

25 Sep 2024

How plant-based, Mediterranean, and Western diets affect gut microbiota and disease

Researchers examine how different dietary components affect the gut microbiome and development of non-communicable diseases.

20 Sep 2024

Review highlights mitochondrial dysfunction in cholestatic liver injury

Bile acids are essential signaling molecules derived from cholesterol metabolism in the liver and are crucial for the digestion and absorption of fats.

16 Sep 2024

Real-world evidence highlights safety profile of tirzepatide in managing type 2 diabetes

As more people with type 2 diabetes (T2D) are taking medications to help manage blood sugar levels and weight loss, concerns about whether these drugs are safe have emerged.

12 Sep 2024

Lipidomics and metabolomics as potential biomarkers for breast cancer progression

This review highlights the potential of lipidomic and metabolomic biomarkers in predicting breast cancer prognosis and therapy response, enhancing patient care.

5 Sep 2024

Researchers demonstrate a new method to combat pancreatic cancer

Researchers at the University of Massachusetts Amherst and UMass Chan Medical School have demonstrated in mice a new method to combat pancreatic cancer.

28 Aug 2024

How diet shapes gut microbiota and affects brain function

Researchers discuss the diet-microbiota-gut-brain axis, which describes the role of both diet and gut microbiota composition on cognitive and emotional health.

26 Aug 2024

SCARB2 deficiency disrupts bile acid metabolism and gut microbiome

The study details the connection between SCARB2 deficiency and gastrointestinal dysfunction, revealing that the loss of SCARB2 leads to alterations in bile acid metabolism and dysbiosis in the gut microbiome. This disruption affects the signaling pathway involving FXR, which normally regulates bile acid synthesis and intestinal lipid absorption. The hyperactive FXR in Scarb2-deficient mice leads to a decrease in epithelial cell turnover and lipid malabsorption, particularly impacting the absorption of vitamin E, which is crucial for maintaining neurological health. The researchers further explored the impact of these changes on the gut-liver axis and found alterations in the expression of genes related to bile acid synthesis.

23 Aug 2024